What is the recommended management of pediatric mastitis, including antibiotic selection for infants younger than 2 weeks versus older children and considerations for MRSA?

Management of Pediatric Mastitis

For neonatal mastitis (infants <2 months), initiate parenteral anti-staphylococcal antibiotics immediately, with vancomycin or clindamycin as first-line agents depending on local MRSA prevalence, and perform surgical drainage for any abscess formation.

Age-Specific Antibiotic Selection

Infants Younger Than 2 Weeks (Neonates)

The primary pathogen in neonatal mastitis is Staphylococcus aureus, with both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains commonly isolated 1, 2. Recent multicenter data suggests most cases present as localized soft tissue infection with very low rates of concurrent serious bacterial infection 3.

Parenteral therapy is the standard approach:

• If local MRSA prevalence is low (<10%): Start with clindamycin 10-13 mg/kg/dose IV every 6-8 hours (total 40 mg/kg/day) 4, 5

  • Transition to oral therapy if strain is susceptible and patient is stable
  • Avoid if concern for bacteremia or endovascular infection

• If local MRSA prevalence is high or unknown: Use vancomycin 15 mg/kg/dose IV every 6 hours 4

  • This is the preferred agent for serious staphylococcal infections in neonates
  • Target trough levels appropriately

• Alternative for MSSA (if confirmed): Flucloxacillin or other anti-staphylococcal penicillins 2

Critical caveat: Well-appearing, afebrile infants with localized mastitis do not require routine blood, urine, or CSF cultures 6. However, any infant with fever or systemic signs requires full sepsis evaluation given age <2 weeks.

Older Infants and Children (>2 Weeks)

For children beyond the neonatal period with mastitis, the approach mirrors treatment of skin and soft tissue infections (SSTI):

Outpatient oral therapy for uncomplicated cases:

• Clindamycin 10-13 mg/kg/dose PO every 6-8 hours (max 40 mg/kg/day) 4

  • Covers both MRSA and streptococci
  • First-line if local clindamycin resistance is <10%

• TMP-SMX 4-6 mg/kg/dose (trimethoprim component) PO every 12 hours 4

  • Excellent MRSA coverage
  • Do NOT use in infants <2 months (contraindicated)
  • Consider adding amoxicillin if streptococcal coverage needed

• Cephalexin 75-100 mg/kg/day in 3-4 doses (if MSSA confirmed) 7

Hospitalized patients with complicated infection:

• Vancomycin 15 mg/kg/dose IV every 6 hours 4, 5
• Clindamycin 10-13 mg/kg/dose IV every 6-8 hours (if clindamycin resistance <10%) 4, 5
• Linezolid: 10 mg/kg/dose IV/PO every 8 hours for children <12 years; 600 mg twice daily for ≥12 years 4, 5

MRSA Considerations

Key decision points for MRSA coverage:

1. Empiric MRSA coverage is indicated when:

   • Local MRSA prevalence is high
   • Purulent drainage present
   • Failed initial beta-lactam therapy
   • Systemic toxicity present
   • Known MRSA colonization or prior infection

2. Clindamycin use requires caution:

   • Only use if local clindamycin resistance among MRSA is <10% 4, 5
   • Perform D-test to detect inducible resistance
   • Avoid for serious infections if inducible resistance present

3. Vancomycin remains the gold standard for serious MRSA infections requiring parenteral therapy 4

Surgical Management

Abscess formation occurs in approximately 50% of neonatal mastitis cases 2. The approach differs by severity:

• Frank abscess: Requires incision and drainage 1, 2

  • Office-based stab incision with drain placement (no packing) for most cases 8
  • Operative drainage only if office procedure not tolerated
  • Surgical drainage may provide cure even with suboptimal antibiotic coverage 2

• Phlegmon without drainable fluid: Antibiotics alone for minimum 10 days 8

• Fluctuance on exam: Attempt aspiration; if thick fluid not amenable to needle drainage, proceed to incision and drainage 8

Important warning: Surgical intervention in infancy may be detrimental to later breast development 1. Optimize medical management to minimize need for extensive procedures.

Treatment Duration

• Uncomplicated mastitis: 7-10 days 4
• With abscess formation: 10-14 days 2, 8
• Severe or complicated infection: Individualize based on clinical response, typically 10-14 days minimum

Monitoring and Follow-up

Expected clinical response:

• Improvement within 48-72 hours of appropriate therapy
• If no improvement, consider:
  • MRSA if not initially covered
  • Inadequate drainage of abscess
  • Alternative diagnosis (granulomatous mastitis in older children is rare but possible)

Culture guidance:

• Obtain cultures from purulent drainage when present 5
• Gram stain can guide initial therapy if available 1
• Blood/urine/CSF cultures unnecessary in well-appearing afebrile infants 6

Common Pitfalls to Avoid

1. Do not use TMP-SMX in infants <2 months - contraindicated due to risk of kernicterus
2. Do not use tetracyclines in children <8 years 4, 5
3. Do not use oral antibiotics as initial therapy in neonates - parenteral route is standard
4. Do not perform extensive surgical excision - simple drainage is sufficient and preserves breast tissue
5. Do not assume streptococcal co-infection - S. aureus is overwhelmingly the dominant pathogen in pediatric mastitis 1, 2, 6